

## **Anti-Spike RBD Reference Antibody (Casirivimab)**

Recombinant Antibody Catalog # APR10007

### **Specification**

## Anti-Spike RBD Reference Antibody (Casirivimab) - Product Information

Application FC, E, FTA

Primary Accession NA

Clonality Monoclonal Isotype IgG1

Calculated MW 145.24 KDa

## Anti-Spike RBD Reference Antibody (Casirivimab) - Additional Information

Target/Specificity
Spike RBD

**Endotoxin** 

 $< 0.001EU/ \mu g$ , determined by LAL method.

**Conjugation** Unconjugated

**Expression system** 

CHO Cell

#### **Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

# Anti-Spike RBD Reference Antibody (Casirivimab) - Protein Information


## Anti-Spike RBD Reference Antibody (Casirivimab) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- <u>Immunofluorescence</u>
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

## Anti-Spike RBD Reference Antibody (Casirivimab) - Images






Anti-Spike RBD Reference Antibody (Casirivimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Spike RBD Reference Antibody (Casirivimab)is more than 99.84% ,determined by SEC-HPLC.



Immobilized 2019nCoV RBD His at 2  $\mu$ g/mL can bind Anti-Spike RBD Reference Antibody (Casirivimab)[EC50=0.006201  $\mu$ g/mL.